Modulation of HIV-1 virulence via the host glucocorticoid receptor: Towards further understanding the molecular mechanisms of HIV-1 pathogenesis

Archives of Virology

Volumn 155, Issue 7, 2010, Pages 1009-1019

  Hapgood, Janet Patricia ^a   Tomasicchio, Michele ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PATHOGENICITY; REVIEW; VIROLOGY; VIRULENCE; VIRUS ENTRY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-1; HUMANS; RECEPTORS, GLUCOCORTICOID; VIRULENCE; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77954244391     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-010-0678-0     Document Type: Review

References (126)

1. De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307-320.
2. Marsden MD, Zack JA (2009) Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63: 7-10.
3. Wainberg MA (2009) Perspectives on antiviral drug development. Antiviral Res 81: 1-5.
4. Montessori V, Press N, Harris M, Akagi L, Montaner JS (2004) Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170: 229-238.
5. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728.
6. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
7. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37: 1112-1118.
8. Spearman P (2006) Current progress in the development of HIV vaccines. Curr Pharm Des 12: 1147-1167.
9. Kaleebu P, Abimiku A, El-Halabi S, Koulla-Shiro S, Mamotte N, Mboup S, Mugerwa R, Nkengasong J, Toure-Kane C, Tucker T, Wassenaar D, Williamson C, Wolday D (2008) African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent. PLoS Med 5: e236.
10. Lu S (2008) Human versus HIV: round 2 defeat in AIDS vaccine development. Expert Rev Vaccines 7: 151-153.
11. Sekaly R (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
12. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
13. Harari A, Bart P, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl J, Esteban M, Heeney J, Frachette M, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63-77.
14. Harari A, Vallelian F, Meylan PR, Pantaleo G (2005) Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174: 1037-1045.
15. Ravanfar P, Mendoza N, Satyaprakash A, Jordan BI (2009) HIV vaccines under study. Dermatol Ther 22: 158-167.
16. Senior K (2008) Back to basics for HIV vaccine research. Lancet Infect Dis 8: 467.
17. Clark JK, Schrader WTOB (1992) Mechanism of steroid hormones. In: Wilson JD (ed) Textbook of Endocrinology. WB Sanders Co., Philadelphia, pp 35-90.
18. Munck A, Guyre PM, Holbrook NJ (1984) Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5: 25-44.
19. Kim YS, Kim J, Kim Y, Lee YH, Kim J, Lee S, Shin SY, Ko J (2008) The role of calpains in ligand-induced degradation of the glucocorticoid receptor. Biochem Biophys Res Commun 374: 373-377.
20. Kino T, Ichijo T, Amin ND, Kesavapany S, Wang Y, Kim N, Rao S, Player A, Zheng Y, Garabedian MJ, Kawasaki E, Pant HC, Chrousos GP (2007) Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol 21: 1552-1568.
21. McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20: 435-459.
22. De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24: 488-522.
23. Smoak KA, Cidlowski JA (2004) Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 125: 697-706.
24. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119: 1198-1208.
25. Pantaleo G, Graziosi C, Fauci AS (1993) New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335.
26. Chrousos GP (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332: 1351-1362.
27. Sellmeyer DE, Grunfeld C (1996) Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 17: 518-532.
28. Zhou J, Cidlowski JA (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70: 407-417.
29. Kumar R, Thompson EB (2005) Gene regulation by the glucocorticoid receptor: structure: function relationship. J Steroid Biochem Mol Biol 94: 383-394.
30. Revollo JR, Cidlowski JA (2009) Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci 1179: 167-178.
31. Stahn C, Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4: 525-533.
32. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E (2010) The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75: 1-12.
33. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP (1995) Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95: 2435-2441.
34. Chrousos GP, Kino T (2005) Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE 2005: pe48.
35. Leo C, Chen JD (2000) The SRC family of nuclear receptor coactivators. Gene 245: 1-11.
36. Lonard DM, Lanz RB, O'Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28: 575-587.
37. Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736.
38. Hayashi R, Wada H, Ito K, Adcock IM (2004) Effects of glucocorticoids on gene transcription. Eur J Pharmacol 500: 51-62.
39. Rogatsky I, Zarember KA, Yamamoto KR (2001) Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20: 6071-6083.
40. Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR (2002) Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci USA 99: 16701-16706.
41. He Y, Simons SS Jr (2007) STAMP, a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression. Mol Cell Biol 27: 1467-1485.
42. Sun Y, Tao Y, Kagan BL, He Y, Stoney Simons S Jr (2008) Modulation of transcription parameters in glucocorticoid receptor-mediated repression. Mol Cell Endocrinol 295: 59-69.
43. Galliher-beckley AJ, Williams JG, Collins JB, Cidlowski JA (2008) Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 28: 7309-7322.
44. Cidlowski JA (2009) Glucocorticoids and their actions in cells. Retina 29: S21-S23.
45. Kino T, Martino MU, Charmandari E, Mirani M, Chrousos GP (2003) Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol 85: 457-467.
46. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T (2002) Hiv-1 Protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity. J Immunol 169: 6361-6368.
47. Ma X, Montaner LJ (2000) Proinflammatory response and IL-12 expression in HIV-1 infection. J Leukoc Biol 68: 383-390.
48. Wiegers K, Schwarck D, Reimer R, Bohn W (2008) Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology 375: 73-84.
49. Kolesnitchenko V, Snart RS (1992) Regulatory elements in the human immunodeficiency virus type 1 long terminal repeat LTR (HIV-1) responsive to steroid hormone stimulation. AIDS Res Hum Retroviruses 8: 1977-1980.
50. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP (1999) The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med 189: 51-62.
51. Sherman MP, DeNoronha C, Pearce D, Greene WC (2000) Human immunode ciency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol 74: 8159-8165.
52. Vanitharani R, Mahalingam S, Ayyavoo V (2001) HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication. Virology 289: 334-342.
53. Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN (2002) Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76: 9724-9734.
54. Mitra D, Sikder SK, Laurence J (1995) Role of glucocorticoid receptor binding sites in the human immunodeficiency virus type 1 long terminal repeat in steroid-mediated suppression of HIV gene expression. Virology 214: 512-521.
55. Ross EK, Buckler-White AJ, Rabson AB, Englund G, Martin MA (1991) Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol 65: 4350-4358.
56. van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E (1997) Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 71: 6113-6127.
57. Berkhout B, Silverman RH, Jeang KT (1989) Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59: 273-282.
58. Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA (1986) The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44: 941-947.
59. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC (1986) The trans-activator gene of HTLV-III is essential for virus replication. Nature 320: 367-371.
60. Ghosh D (1992) Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat. J Virol 66: 586-590.
61. Soudeyns H, Geleziunas R, Shyamala G, Hiscott J, Wainberg MA (1993) Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology 194: 758-768.
62. Kino T, Kopp JB, Chrousos GP (2000) Glucocorticoids suppress human immunodeficiency virus type-1 long terminal repeat activity in a cell type-specific, glucocorticoid receptor-mediated fashion: direct protective effects at variance with clinical phenomenology. J Steroid Biochem Mol Biol 75: 283-290.
63. Markham PD, Salahuddin SZ, Popovic M, Patel A, Veren K, Fladager A, Orndorff S, Gallo RC (1985) Advances in the isolation of HTLV-III from patients with AIDS and AIDS-related complex and from donors at risk. Cancer Res 45: 4588s-4591s.
64. Markham PD, Salahuddin SZ, Veren K, Orndorff S, Gallo RC (1986) Hydrocortisone and some other hormones enhance the expression of HTLV-III. Int J Cancer 37: 67-72.
65. Soudeyns H, Wainberg MA (1997) Effects of RU486 on HIV-1 replication. Nat Med 3: 1302-1303.
66. Verdin E, Paras P, van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12: 3249-3259.
67. van Lint C, Emiliani S, Ott M, Verdin E (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15: 1112-1120.
68. Agostini I, Navarro JM, Rey F, Bouhamdan M, Spire B, Vigne R, Sire J (1996) The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J Mol Biol 261: 599-606.
69. Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA (1999) Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol 73: 4101-4109.
70. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ (1995) Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 270: 25564-25569.
71. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 69: 6304-6313.
72. Ayyavoo V, Mahalingam S, Rafaeli Y, Kudchodkar S, Chang D, Nagashunmugam T, Williams WV, Weiner DB (1997) HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol 62: 93-99.
73. Tcherepanova I, Starr A, Lackford B, Adams MD, Routy J, Boulassel MR, Calderhead D, Healey D, Nicolette C (2009) The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PloS One 4: e5853.
74. Janket ML, Manickam P, Majumder B, Thotala D, Wagner M, Schafer EA, Collman RG, Srinivasan A, Ayyavoo V (2004) Differential regulation of host cellular genes by HIV-1 viral protein R (Vpr): cDNA microarray analysis using isogenic virus. Biochem Biophys Res Commun 314: 1126-1132.
75. Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, Noronha CM, Greene WC, Wray V, Schubert U (2000) Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G 2 cell cycle arrest. J Biol Chem 275: 32016-32026.
76. Levy DN, Refaeli Y, MacGregor RR, Weiner DB (1994) Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 91: 10873-10877.
77. Ganser-Pornillos BK, Yeager M, Sundquist WI (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18: 203-217.
78. Gramberg T, Sunseri N, Landau NR (2009) Accessories to the crime: recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep 6: 36-42.
79. Malim MH (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364: 675-687.
80. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V (2009) HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5: e1000574.
81. Kino T, Nordeen SK, Chrousos GP (1999) Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300. J Steroid Biochem Mol Biol 70: 15-25.
82. Thotala D, Schafer EA, Majumder B, Janket ML, Wagner M, Srinivasan A, Watkins S, Ayyavoo V (2004) Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology 328: 89-100.
83. Kino T, Pavlakis GN (2004) Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol 23: 193-205.
84. Kino T, Martino MU, Charmandari E, Ichijo T, Chrousos GP (2005) HIV-1 accessory protein Vpr inhibits the effect of insulin on the foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 54: 23-31.
85. Kamata M, Watanabe N, Nagaoka Y, Chen IS (2008) Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2. J Virol 82: 5672-5682.
86. Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB (1997) HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 3: 1117-1123.
87. Schafer EA, Venkatachari NJ, Ayyavoo V (2006) Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Antiviral Res 72: 224-232.
88. Kauppi B, Jakob C, Färnegårdh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist A, Thorell S, Ohman L, Greer J, Gustafsson J, Carlstedt-Duke J, Carlquist M (2003) The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 278: 22748-22754.
89. Fakruddin JM, Laurence J (2005) HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 150: 67-78.
90. Muthumani K, Choo AY, Premkumar A, Hwang DS, Thieu KP, Desai BM, Weiner DB (2005) Human immunodeficiency virus type 1 (HIV-1) Vpr- regulated cell death: insights into mechanism. Cell Death Differ 12: 962-970.
91. Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63: 60-72.
92. Patel CA, Mukhtar M, Pomerantz RJ (2000) Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74: 9717-9726.
93. Majumder B, Venkatachari NJ, Schafer EA, Janket ML, Ayyavoo V (2007) Dendritic Cells Infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha. J Virol 81: 7388-7399.
94. Kim KD, Choe YK, Choe IS, Lim JS (2001) Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J Leukoc Biol 69: 426-434.
95. Kotitschke A, Sadie-Van Gijsen H, Avenant C, Fernandes S, Hapgood JP (2009) Genomic and nongenomic cross talk between the gonadotropin-releasing hormone receptor and glucocorticoid receptor signaling pathways. Mol Endocrinol 23: 1726-1745.
96. Avenant C, Kotitschke A, Hapgood JP (2010) Glucocorticoid receptor phosphorylation modulates transcription efficacy through GRIP-1 recruitment. Biochemistry 49: 972-985.
97. Agostini I, Popov S, Hao T, Li JH, Dubrovsky L, Chaika O, Chaika N, Lewis R, Bukrinsky M (2002) Phosphorylation of Vpr Regulates HIV Type 1 Nuclear Import and Macrophage Infection. AIDS Res Hum Retroviruses 18: 283-288.
98. Ishaq M, DeGray G, Mou K, Aguilera A, Yang J, Lempicki RA, Hazen A, Natarajan V (2007) Zap70 signaling pathway mediates glucocorticoid receptor-dependent transcriptional activation: role in the regulation of annexin 1 expression in T cells. J Immunol 179: 3851-3858.
99. Collingwood TN, Urnov FD, Wolffe AP (1999) Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23: 255-275.
100. Ratajczak T, Ward BK, Minchin RF (2003) Immunophilin Chaperones in Steroid Receptor Signalling. Curr Top Med Chem 3: 1348-1357.
101. Tatro ET, Everall IP, Masliah E, Hult BJ, Lucero G, Chana G, Soontornniyomkij V, Achim CL (2009) Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol 4: 218-226.
102. Wang J, Shackelford JM, Selliah N, Shivers DK, O'Neill E, Garcia JV, Muthumani K, Weiner D, Yu X, Gabuzda D, Finkel TH (2008) The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol 27: 267-277.
103. Hapgood JP, Koubovec D, Louw A, Africander D (2004) Not all progestins are the same: implications for usage. Trends Pharmacol Sci 25: 554-557.
104. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP (2005) Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 242: 23-32.
105. Ronacher K, Hadley K, Avenant C, Stubsrud E, Louw A, Hapgood JP (2009) Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol 299: 219-231.
106. Hewitt RG, Parsa N, Gugino L (2001) Women's health. The role of gender in HIV progression. AIDS Read 11: 29-33.
107. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J (1999) Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 5: 535-541.
108. Greenblatt RM, Ameli N, Grant RM, Bacchetti P, Taylor RN (2000) Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis 181: 82-90.
109. Kojic EM, Cu-Uvin S (2007) Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 19: 464-469.
110. Asin SN, Heimberg AM, Eszterhas SK, Rollenhagen C, Howell AL (2008) Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses 24: 701-716.
111. Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194: S51-S58.
112. Andrieu JM, Lu W, Levy R (1995) Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 171: 523-530.
113. McComsey GA, Whalen CC, Mawhorter SD, Asaad R, Valdez H, Patki AH, Klaumunzner J, Gopalakrishna KV, Calabrese LH, Lederman MM (2001) Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 15: 321-327.
114. Orlikowsky TW, Wang ZQ, Dudhane A, Dannecker GE, Niethammer D, Wormser GP, Hoffmann MK, Horowitz HW (2001) Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons. J Infect Dis 184: 1328-1330.
115. Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM (2003) A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr 32: 281-286.
116. Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC (2003) A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J Infect Dis 188: 531-536.
117. Andrieu J, Lu W (2004) Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2: 17.
118. Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB, Ducar C, Ellner JJ, Whitworth JA, Mugerwa R, Johnson JL, Okwera A (2004) A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 190: 869-878.
119. Panayotakopoulos GD, Day S, Peters BS, Kulasegaram R (2006) Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines. Int J STD AIDS 17: 567-568.
120. Rosen J, Miner JN (2005) The search for safer glucocorticoid receptor ligands. Endocr Rev 26: 452-464.
121. Fauci AS (2008) 25 years of HIV. Nature 453: 289-290.
122. Geeraert L, Kraus G, Pomerantz RJ (2008) Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 59: 487-501.
123. Amini S, Saunders M, Kelley K, Khalili K, Sawaya BE (2004) Interplay between HIV-1 Vpr and Sp1 Modulates p21 (WAF1) gene expression in human astrocytes. J Biol Chem 279: 46046-46056.
124. Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ (1998) HIV transcriptional activation by the accessory protein, Vpr, is mediated by the p300 co-activator. Proc Natl Acad Sci USA 95: 5281-5286.
125. Marcello A, Zoppé M, Giacca M (2001) Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life 51: 175-181.
126. Kino T, Tsukamoto M, Chrousos GP (2002) Transcription factor TFIIH components enhance the GR coactivator activity but not the cell cycle-arresting activity of the human immunodeficiency virus type-1 protein Vpr. Biochem Biophys Res Commun 298: 17-23.